12 Jul Lazurite® Names Dr. James Voos to Medical Advisory Board 

CLEVELAND–(BUSINESS WIRE)–Medical device and technology company Lazurite today announced that James Voos, M.D. has joined the company’s medical advisory board. 

Dr. Voos currently serves as chair of the orthopedics departments at University Hospitals and Case Western Reserve University, which includes overseeing their renowned orthopedic training programs and research divisions. He was recently elected vice president of the NFL Physicians Society (NFLPS) and serves as the head team physician for the Cleveland Browns. 

“We are honored to have Dr. Voos join our team,” Lazurite CEO and cofounder Eugene Malinskiy said. “He has made significant contributions in the product refinement of the ArthroFree® Wireless Surgical Camera System, particularly for our orthopedics and sports medicine target markets.” 

The ArthroFree System is the first wireless surgical camera to receive market clearance from the U.S. Food and Drug Administration for arthroscopy and general endoscopy. By eliminating conventional camera cables that tether surgeons to the surgical tower and hinder their movement, the ArthroFree System is expected to increase OR efficiency, improve OR safety and lower customer costs. More than 100 surgeries have now been performed using the ArthroFree System. 

“I’m excited about joining the Lazurite team as the company brings the ArthroFree System to market,” said Dr. James Voos. “I look forward to making contributions to the evolution of the OR from wired to wireless surgical cameras.” 

Dr. Voos earned his medical degree from the University of Kansas where he was elected president of the Alpha Omega Alpha honor society. He went on to complete an orthopedic surgery residency and sports medicine fellowship at the U.S. News & World Report #1 ranked Hospital for Special Surgery in New York. While in New York, he served as assistant team physician for the New York Giants and WNBA New York Liberty. Previously, he was a team physician for the Kansas City Chiefs and head physician for the Kansas City Ballet. 

Dr. Voos has published over 100 scientific papers and book chapters on topics such as ACL reconstruction, shoulder instability and Tommy John surgery, and has obtained FDA approval for a study to treat early arthritis and cartilage injuries using stem cells. He has a passion for advancing the safety and education of athletes with additional expertise in the use of wearable technology, injury prevention and sports performance.  He is an investor in Lazurite.

He is a participant on a Human Factors usability validation study of the ArthroFree® Wireless Surgical Camera System.

About Lazurite 

Lazurite is a medical device and technology company. Its ArthroFree® System—the wireless camera for arthroscopy and general endoscopy—is designed for surgeons seeking surgical tools for greater agility in the OR. ArthroFree is drop-in compatible with current OR technologies, and it promises to eliminate cable-related patient burns, OR fires, and staff trips and falls. With the ArthroFree System, Lazurite ushers in the wireless era of surgical visualization. Lazurite’s intellectual property portfolio also includes the low-heat Meridiem light technology and products in development. The pre-revenue company is located in Cleveland, OH (est. 2015), and to date has raised ~$30M from institutional investors, family offices, and more than 75 physician champions. The mission: solve impossible problems to improve people’s lives. The three-year vision (by 2026): Modernize 1,000 ORs for the wireless age. For more information, see: 
https://lazurite.co. 

Forward-Looking Statements 

This press release includes “forward-looking statements.” Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “expect,” “may,” “should,” “will,” “designed,” “promises,” and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding the expected impact of the ArthroFree System on the field of minimally invasive surgery, and particularly arthroscopic surgery, and our future sales of the ArthroFree System. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. 

Lazurite®, ArthroFree®, and Meridiem® are registered trademarks of Lazurite Holdings LLC. 

Media Center 

Visit lazurite.co/media for videos, logos, images, fact sheets, bios and more. 

Contacts 

Patrick Gallagher
+1 (216) 233-7473
p.gallagher@lazurite.co 

Lazurite:
+1 (216) 334-3127
contact@lazurite.co 

SOURCE: Business Wire, Lazurite, July 12 2023

To find out more news from the industry head over to our news section – orthocg.com/news